Home » News

Stellarray Phase III Contract for Blood Irradiator

14 November 2017

Stellarray, Inc., an Austin developer of novel x-ray sources, announced today it has been awarded a contract with the U.S. Department of Energy’s National Nuclear Security Administration (NNSA) to complete development of its self-contained blood irradiator (SCBI), which will help eliminate the need for dangerous radioactive isotopes. The 18-month contract is for Phase III of the small business innovation research project the company began for NNSA in 2014 to develop this irradiator. The objective of Phase III is to finish testing the x-ray sources, deploy beta test units to three irradiator users at hospitals and blood banks, and complete system regulatory testing.

Stellarray’s Self-Contained Blood Irradiator (SCBI) will provide blood banks, hospitals, oncology centers and other blood transfusion practices a reliable alternative to the radioactive isotope irradiators now used to inactivate leukocytes for the prevention of graft-versus-host disease (GVHD). These irradiators use cesium 137, which has been identified as a national security hazard since it is the most likely material for a radioactive dispersal device (dirty bomb). The heart of SCBI is Stellarray’s patented Flat Panel X-ray Source (FPXS), which uses a specially engineered array of cathodes, instead of the single cathode in an x-ray tube, to make x-rays across a broad anode target that can be externally cooled. SCBI is designed for low-cost, reliable operation in a shielded cabinet about one third the size and one fifth the weight of alternative irradiators. No special electrical power or cooling connections are required, and, since it is not radioactive, there is no need for the elaborate security measures that burden users of isotope irradiators.

Stellarray began operations in 2008 to make novel radiation sources and systems using them. The company has developed manufacturing systems for its novel FPXS and is also working on research irradiators to replace radioactive isotopes. The company also develops digital “smart x-ray sources” for next generation computed tomography and phase contrast imaging systems. For further information please contact eaton@stellar-ray.com.